Norepinephrine (medication)
Systematic (IUPAC) name | |
---|---|
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol | |
Clinical data | |
Trade names | Levarterenol, Levophed, Norepin |
AHFS/Drugs.com | monograph |
Licence data | US FDA:link |
Pregnancy category | |
Legal status | |
Routes of administration | Intravenous |
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Urine (84–96%) |
Identifiers | |
CAS Number | 51-41-2 |
ATC code | C01CA03 |
PubChem | CID 439260 |
IUPHAR/BPS | 505 |
DrugBank | DB00368 |
ChemSpider | 388394 |
UNII | X4W3ENH1CV |
KEGG | D00076 |
ChEBI | CHEBI:18357 |
ChEMBL | CHEMBL1437 |
Synonyms |
Noradrenaline (R)-(–)-Norepinephrine l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol |
Chemical data | |
Formula | C8H11NO3 |
Molar mass | 169.18 g/mol |
| |
| |
Physical data | |
Density | 1.397±0.06 g/cm3 |
Melting point | 217 °C (423 °F) (decomposes) |
Boiling point | 442.6 °C (828.7 °F) ±40.0°C |
(verify) |
Norepinephrine, also known as noradrenaline, is a medication used to treat people with very low blood pressure. It is manufactured with the same formulation as the hormone and neurotransmitter norepinephrine. It is given intravenously.
At high doses, and especially when it is combined with other vasopressors, it can lead to limb ischemia and limb death.
Medical uses
Norepinephrine is used mainly as a sympathomimetic drug to treat people in vasodilatory shock states such as septic shock and neurogenic shock, while showing fewer adverse side-effects compared to dopamine treatment.[1]
Mechanism of action
It acts on both α1 and α2 adrenergic receptors to cause blood vessel contraction. Its effects are often limited to the increasing of blood pressure through agonist activity on α1 and α2 receptors, and causing a resultant increase in peripheral vascular resistance.
Names
Norepinephrine is the INN while noradrenaline is the BAN.
References
- ↑ De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL (March 2010). "Comparison of dopamine and norepinephrine in the treatment of shock". The New England Journal of Medicine 362 (9): 779–89. doi:10.1056/nejmoa0907118. PMID 20200382.
|